JP Morgan Chase’s bluebird bio BLUE Stock Holding History

JP Morgan Chase’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-16,920	Closed	-$1.11M	–	7467
2023 Q2	$1.11M	Buy	+16,920	New	+$1.24M	﹤0.01%	3981
2020 Q1	–	Sell	-3,860	Closed	-$4.39M	–	5306
2019 Q4	$4.39M	Buy	+3,860	New	+$4.2M	﹤0.01%	2787
2019 Q3	–	Sell	-1,737	Closed	-$2.79M	–	5728
2019 Q2	$2.79M	Buy	+1,737	New	+$3M	﹤0.01%	3143
2019 Q1	–	Sell	-6,307	Closed	-$8.11M	–	5763
2018 Q4	$8.11M	Buy	6,307 +2,887	+84%	+$4.43M	﹤0.01%	2191
2018 Q3	$6.47M	Buy	3,420 +2,795	+447%	+$5.77M	﹤0.01%	2539
2018 Q2	$1.27M	Buy	+625	New	+$1.42M	﹤0.01%	3690
2018 Q1	–	Sell	-2,084	Closed	-$4.81M	–	5381
2017 Q4	$4.81M	Buy	+2,084	New	+$4.23M	﹤0.01%	2712

Other funds holding BLUE

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's BLUE Position: Q2 2025 in Review

JP Morgan Chase sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 26,870 shares — an estimated $131K sold.

JP Morgan Chase first reported a position in BLUE in Q3 2013 and held it in 44 quarters. The position peaked at $52.1M in Q2 2021. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.

JP Morgan Chase reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
JP Morgan Chase sold 26,870 bluebird bio shares in Q2 2025, an estimated $131K.
JP Morgan Chase first reported a position in bluebird bio in Q3 2013 and held it in 44 quarters.
JP Morgan Chase's bluebird bio position peaked at $52.1M in Q2 2021.
3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.